Our study identified three new diagnostic and prognostic biomarkers of invasion risk (SEMA3F, NRP1 and NRP2) in DCIS patients and paves the way for new therapeutic strategies to maintain early BC at a noninvasive stage, a more affordable disease in clinical terms. Here, NRP1 is linked to breast cancer.